Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay.
In vitro-synthesized carbamylated and acetylated hemoglobins interfered in assays of glycohemoglobin by HPLC and electrophoresis but had no effects on results obtained by affinity chromatography and enzyme immunoassay. Correlations between long-term serum urea concentrations and glycohemoglobin percentages revealed that, in vivo, carbamylated hemoglobin equivalent to 0.063% of total hemoglobin is formed for every 1 mmol/L of serum urea. The use of acetylsalicylate, either chronically in small doses (200-300 mg/day) or for 1 week at 2000 mg/day, did not cause significant interference from acetylhemoglobin, formed in vivo. We conclude that interference from carbamylated hemoglobin explains only a small part of existing discrepancies between results of glycohemoglobin assays in current use. The interfering effect of acetylhemoglobin formed in vivo with acetyl-CoA as substrate is as yet unknown.
Weykamp
C W
CW
Department of Clinical Chemistry, Queen Beatrix Hospital, Winterswijk, The Netherlands.
Penders
T J
TJ
Siebelder
C W
CW
Muskiet
F A
FA
van der Slik
W
W
D000107:Acetylation; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000097:blood / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D002845:Chromatography; D002846:Chromatography, Affinity; D002851:Chromatography, High Pressure Liquid; D004586:Electrophoresis; D006442:Glycated Hemoglobin / Q000032:analysis*; D006441:Hemoglobin A / Q000031:analogs & derivatives*; D006454:Hemoglobins; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D011786:Quality Control; D014508:Urea / Q000097:blood
D001241:Aspirin; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D006441:Hemoglobin A; D006454:Hemoglobins; D014508:Urea; C058244:acetylated hemoglobin; C022017:hemoglobin A, carbamylated